IceCure Medical Ltd., which develops next-generation minimally invasive cryoablation technology that destroys tumors by freezing, began trading on the Nasdaq Capital Market on Thursday under the ticker symbol ICCM, the company announced Thursday.
Follow Israel Hayom on Facebook and Twitter
"We are proud and excited to achieve the milestone of listing our shares on the Nasdaq, which represents the latest in a series of significant accomplishments for IceCure this year," commented Eyal Shamir, Chief Executive Officer of IceCure. "We believe that the Nasdaq listing of our shares will help expand our global reach and raise our profile among investors and business partners, alike."
"This listing will make it easier for US-based and international investors to be part of the IceCure story, provide more liquidity to our stock and help raise our visibility among US and global investors, as well as the analyst community," added Ronen Tsimerman, Chief Financial Officer of IceCure.
